1921
Volume 78, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Azithromycin, an azalide antibiotic, is highly concentrated within different phagocytic cells, especially macrophages. The potential antileishmanial activity of azithromycin against three species of from the New World was assessed using models. Azithromycin decreased viability of promastigote cultures of () , () and () as determined by the colorimetric Alamar blue assay. In amastigote intracellular cultures, a significant decrease in infected macrophages counts was observed for all three species with IC of 20.83 (27 μ mol/L), 2.18 (2.7 μmol/L), and 6.12 (7.8 μmol/L) μg/mL, respectively. Azithromycin showed activity against . (.) , . (.) and . (.) and may offer an alternative to current leishmaniasis treatment.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2008.78.745
2008-05-01
2017-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/78/5/0780745.html?itemId=/content/journals/10.4269/ajtmh.2008.78.745&mimeType=html&fmt=ahah

References

  1. Berman JD, 2003. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 16 : 397–401.
  2. Croft SL, Seifert K, Yardley V, 2006. Current scenario of drug development for leishmaniasis. Indian J Med Res 123 : 399–410.
  3. Akuffo H, Dietz M, Teklemariam S, Tadesse T, Amare G, Berhan TY, 1990. The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 84 : 532–534.
  4. Weinrauch L, Livshin R, el-On J, 1987. Ketoconazole in cutaneous leishmaniasis. Br J Dermatol 117 : 666–668.
  5. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH, 2002. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 346 : 891–895.
  6. Periti P, Mazzei T, Mini E, Novelli A, 1993. Adverse effects of macrolide antibacterials. Drug Saf 9 : 346–364.
  7. Gladue RP, Bright GM, Isaacson RE, Newborg MF, 1989. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33 : 277–282.
  8. Foulds G, Madsen P, Cox C, Shepard R, Johnson R, 1991. Concentration of azithromycin in human prostatic tissue. Eur J Clin Microbiol Infect Dis 10 : 868–871.
  9. Scheinfeld NS, Tutrone WD, Torres O, Weinberg JM, 2004. Macrolides in dermatology. Dis Mon 50 : 350–368.
  10. Zuckerman JM, 2000. The newer macrolides: azithromycin and clarithromycin. Infect Dis Clin North Am 14 : 449–462.
  11. Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Dev V, Patel K, Mohapatra MK, Lakhani J, Benner R, Lele C, Patki K, 2005. A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J Infect Dis 191 : 1582–1588.
  12. Nakornchai S, Konthiang P, 2006. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Trop 100 : 185–191.
  13. Miller RS, Wongsrichanalai C, Buathong N, McDaniel P, Walsh DS, Knirsch C, Ohrt C, 2006. Effective treatment of uncomplicated Plasmodium falciparum malaria with azithromycin-quinine combinations: a randomized, dose-ranging study. Am J Trop Med Hyg 74 : 401–406.
  14. Krolewiecki A, Leon S, Scott P, Abraham D, 2002. Activity of azithromycin against Leishmania major in vitro and in vivo. Am J Trop Med Hyg 67 : 273–277.
  15. Tanyuksel M, Bas AL, Araz E, Aybay C, 2003. Determination of intracellular efficacies of azithromycin against Leishmania major infection in human neutrophils in vitro. Cell Biochem Funct 21 : 93–96.
  16. Prata A, Silva-Vergara ML, Costa L, Rocha A, Krolewiecki A, Silva JC, Paula DE, Pimenta EV, Junior FG, Giraldo LE, 2003. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. Rev Soc Bras Med Trop 36 : 65–69.
  17. Silva-Vergara ML, Silva Ld EA, Maneira FR, da Silva AG, Prata A, 2004. Azithromycin in the treatment of mucosal leishmaniasis. Rev Inst Med Trop Sao Paulo 46 : 175–177.
  18. Krolewiecki AJ, Romero HD, Cajal SP, Abraham D, Mimori T, Matsumoto T, Juarez M, Taranto NJ, 2007. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. Am J Trop Med Hyg 77 : 640–646.
  19. Layegh P, Yazdanpanah MJ, Vosugh EM, Pezeshkpoor F, Shakeri MT, Moghiman T, 2007. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Am J Trop Med Hyg 77 : 99–101.
  20. Mikus J, Steverding D, 2000. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 48 : 265–269.
  21. Huber W, Koella JC, 1993. A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites. Acta Trop 55 : 257–261.
  22. Croft SL, Yardley V, Kendrick H, 2002. Drug sensitivity of Leishmania species: some unresolved problems. Trans R Soc Trop Med Hyg Apr 96 (Suppl1) : S127–S129.
  23. McMahon-Pratt D, Alexander J, 2004. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? Immunol Rev 201 : 206–224.
  24. Cantin L, Chamberland S, 1993. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother 37 : 1993–1996.
  25. Gingras BA, Jensen JB, 1992. Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Am J Trop Med Hyg 47 : 378–382.
  26. Biswas S, 2001. In-vitro antimalarial activity of azithromycin against chloroquine sensitive and chloroquine resistant Plasmodium falciparum. J Postgrad Med 47 : 240–243.
  27. Orth C, Wllingmyre GD, Lee P, Knirsh C, Milhous W, 2002. Assessment of azithromycin in combination with other anti-malarial drugs Plasmodium falciparum in vitro. Antimicrob Agents Chemother 46 : 2518–2524.
  28. Blais J, Garneau V, Chamberland S, 1993. Inhibition of Toxo-plasma gondii protein synthesis by azithromycin. Antimicrob Agents Chemother 37 : 1701–1703.
  29. Foulds G, Shepard RM, Johnson RB, 1990. The pharmacokinetics of azithromycin in human prostatic tissue. J Antimicrob Chemother 25 (Suppl A) : 73–82.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2008.78.745
Loading
/content/journals/10.4269/ajtmh.2008.78.745
Loading

Data & Media loading...

  • Received : 06 Nov 2007
  • Accepted : 16 Feb 2008

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error